You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim
Medtronic
McKesson
Mallinckrodt
McKinsey

Last Updated: September 22, 2020

DrugPatentWatch Database Preview

Patent: 8,691,225

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,691,225
Title:Antibodies against the ectodomain of ErbB3 and uses thereof
Abstract: The present invention provides a novel class of antibodies and antigen binding fragments thereof that bind the extracellular domain of ErbB3 receptor and inhibit various ErbB3 functions. For example, the antibodies and antigen binding fragments described herein are capable of binding to the receptor designated ErbB3 and inhibiting EGF-like ligand mediated phosphorylation of the receptor. Such antibodies and antigen binding fragments thereof have the useful characteristic of inhibiting the proliferation of cancer cells expressing ErbB3.
Inventor(s): Schoeberl; Birgit (Cambridge, MA), Nielsen; Ulrik (Quincy, MA), Feldhaus; Michael (Grantham, NH), Muruganandam; Arumugam (Bangalore, IN), Buckler; David (Chester, NJ)
Assignee: Merrimack Pharmaceuticals, Inc. (Cambridge, MA)
Application Number:12/545,279
Patent Claims:see list of patent claims

Details for Patent 8,691,225

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Start Trial Merrimack Pharmaceuticals, Inc. (Cambridge, MA) 2027-02-16 RX Orphan search
Imclone ERBITUX cetuximab VIAL; INTRAVENOUS 125084 001 2004-06-18   Start Trial Merrimack Pharmaceuticals, Inc. (Cambridge, MA) 2027-02-16 RX Orphan search
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 001 2006-09-27   Start Trial Merrimack Pharmaceuticals, Inc. (Cambridge, MA) 2027-02-16 RX search
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 002 2006-09-27   Start Trial Merrimack Pharmaceuticals, Inc. (Cambridge, MA) 2027-02-16 RX search
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 003 2006-09-27   Start Trial Merrimack Pharmaceuticals, Inc. (Cambridge, MA) 2027-02-16 RX search
Genentech Inc HERCEPTIN HYLECTA trastuzumab; hyaluronidase-oysk INJECTABLE;SUBCUTANEOUS 761106 001 2019-02-28   Start Trial Merrimack Pharmaceuticals, Inc. (Cambridge, MA) 2027-02-16 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Dow
Colorcon
Johnson and Johnson
Moodys
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.